Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy

被引：70
|
作者：
Queirolo, Paola [1 ]
Boutros, Andrea [1 ]
Tanda, Enrica [1 ]
Spagnolo, Francesco [1 ]
Quaglino, Pietro [2 ]
机构：
[1] IRCCS Osped Policlin San Martino, Skin Canc Unit, Genoa, Italy
[2] Univ Turin, Med Sch, Dept Med Sci, Dermatol Clin, Turin, Italy
来源：
SEMINARS IN CANCER BIOLOGY | 2019年 / 59卷
关键词：
Melanoma; Immunotherapy; Immune-checkpoint inhibitors; CTLA-4; PD-1; Biomarker; CUTANEOUS ADVERSE EVENTS; OPEN-LABEL; COMBINED NIVOLUMAB; TUMOR RESPONSE; CHECKMATE; 037; DOUBLE-BLIND; IPILIMUMAB; PEMBROLIZUMAB; SURVIVAL; PHASE-3;
D O I：
10.1016/j.semcancer.2019.08.001
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Melanoma has always been described as an immunogenic tumor. Despite that, until 2011 the standard of care in metastatic melanoma was chemotherapy, with low response rates and no clear impact on overall survival. Melanoma was the first cancer type to drive the use of immune-checkpoint inhibitors into clinical practice, which revolutionized the therapeutic paradigm not only in melanoma, but also in an increasing number of tumors. In this review, the preclinical bases and the main clinical studies that led to the approval of immune-checkpoint inhibitors in advanced melanoma will be described with insights on novel combinations of treatments and on prognostic and predictive biomarkers.
引用
收藏
页码：290 / 297
页数：8
相关论文
共 50 条
  • [31] Combination Immunotherapy of peptide vaccine and immune-checkpoint blockade therapy for treatment of gastric cancer
    Kua, Ley-Fang
    Mimura, Kousaku
    Kono, Koji
    Yong, Wei-Peng
    CANCER SCIENCE, 2018, 109 : 277 - 277
  • [32] Association of immune-related adverse events with immune-checkpoint inhibitors and treatment response in melanoma patients.
    Rodriguez, Benigno
    Martinez-Herrera, Jose Fabian
    Zepeda, Lorena Lopez
    Olivares, Guillermo
    Villalobos, Alberto
    Perez, Fernando
    Limas, Christian Patricio Camacho
    Serrano, Juan Alberto
    Villamayor, Omar Serrano
    Lopez, Ervin Saul Enciso
    Gerson, Daniela Shveid
    Sanchez, Efrain Isaias Camarin
    Molina, Diana Bonilla
    Cabrera, Juan Manuel Tovar
    Nehmad, Cecilia
    Whaley, Juan Jose Juarez -Vignon
    Gerson, Raquel
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
    Passiglia, Francesco
    Reale, Maria Lucia
    Cetoretta, Valeria
    Novello, Silvia
    IMMUNOTARGETS AND THERAPY, 2021, 10 : 9 - 26
  • [34] Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
    Borelli, Beatrice
    Antoniotti, Carlotta
    Carullo, Martina
    Germani, Marco Maria
    Conca, Veronica
    Masi, Gianluca
    CANCERS, 2022, 14 (20)
  • [35] Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
    Mesti, Tanja
    Grasic Kuhar, Cvetka
    Ocvirk, Janja
    BIOMEDICINES, 2023, 11 (03)
  • [36] Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma
    Bouchereau, Sarah
    Chaplain, Louise
    Fort, Magali
    Beauchet, Alain
    Sidibe, Thomas
    Chapalain, Marie
    Gonzalez-Lara, Leire
    Longvert, Christine
    Blom, Astrid
    Saiag, Philippe
    Funck-Brentano, Elisa
    BRITISH JOURNAL OF CANCER, 2021, 125 (07) : 948 - 954
  • [37] Symptomatic aseptic sinusitis induced by immune checkpoint inhibitors for metastatic melanoma treatment
    Tzoumpa, Sofia
    Villette, Beatrice
    Granel-Brocard, Florence
    Dutriaux, Caroline
    Memmi, Alexandre
    Jeudy, Geraldine
    Tafani, Victor
    Saint-Jean, Melanie
    Nardin, Charlee
    Funck-Brentan, Elisa
    Le Corre, Yannick
    Quereux, Gaelle
    Maubec, Eve
    IMMUNOTHERAPY, 2024,
  • [38] Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma
    Sarah Bouchereau
    Louise Chaplain
    Magali Fort
    Alain Beauchet
    Thomas Sidibé
    Marie Chapalain
    Leire Gonzalez-Lara
    Christine Longvert
    Astrid Blom
    Philippe Saiag
    Elisa Funck-Brentano
    British Journal of Cancer, 2021, 125 : 948 - 954
  • [39] New Developments in the Treatment of Metastatic Melanoma: Immune Checkpoint Inhibitors and Targeted Therapies
    Azijli, Kaamar
    Stelloo, Ellen
    Peters, Godefridus J.
    Van den Eertwegh, Alfons J. M.
    ANTICANCER RESEARCH, 2014, 34 (04) : 1493 - 1505
  • [40] Checkpoint inhibitors in treatment of metastatic mucosal melanoma
    Bin Lian
    Jun Guo
    CHINESE CLINICAL ONCOLOGY, 2014, 3 (03)
12345